Fig. 1From: Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine modelDox release profile of Dox liposomes and Dox immunoliposomes in FBS. Each point represents mean ± SD of three different batches analysed in duplicate. No statistical differences were found. Dox: Doxorubicin; LPD: conventional Dox liposomes; LPF: targeted Dox liposomes; FBS: fetal bovine serumBack to article page